In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
Everyday Health on MSN
Blockbuster Cancer Drug Keytruda Now Available as a Time-Saving Shot
Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...
Though MSD's subcutaneous Keytruda is more patient-centric, analysts are sceptical of the drug’s capacity to stave off ...
The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy ...
Merck ( NYSE: MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The U.S. Food and Drug Administration has approved Merck & Co.’s KEYTRUDA QLEX, a subcutaneous injection for adult patients ...
FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback